Table 1.
Main characteristics of included studies
| Reference | Year | Location | Study design | n | Jaw | Age, years (mean ± SD or range) | Total surgery time, minutes (mean ± SD) | Dexmedetomidine dosage | Control (type) | Evaluation indicator |
|---|---|---|---|---|---|---|---|---|---|---|
| Cheung et al26 | 2011 | Hong Kong | RCT (parallel) | 60 | Mand | 27.1±6.2D 26.9±5.7P |
25.6±13.6D 24.7±12.5P |
1.0 μg/kg | 0.9% saline | OAA/S, BIS, pain, HR, SBP |
| Gu et al27 | 2014 | Nanjing, China | RCT (parallel) | 30 | Mand | 25–35 | 27±6D 28±7P |
1.5 μg/kg | 0.9% saline | OAA/S, HR, SBP |
| Nooh et al25 | 2013 | Riyadh, Saudi Arabia | RCT (split mouth) | 18 | Mand | 25±3.9 | 28±9D 30±7P |
1.5 μg/kg | Water | OAA/S, BIS, pain, HR, SBP |
| Ryu et al24 | 2016 | Seoul, South Korea | RCT (parallel) | 240 | Mand | 26.0±8.1D 25.6±1.6P |
20.1±10.3D 20.3±11.5P |
1.5 μg/kg | No treatment | Pain, adverse events, patient satisfaction, and BIS |
| Shetty and Aggarwal23 | 2016 | Mysore, India | RCT (split mouth) | 15 | Mand | 18–35 | NR | 1.5 μg/kg | 0.9% saline | OAA/S, pain |
Notes:
D
Dexmedetomidine;
P
placebo. Dexmedetomidine administered intranasally.
Abbreviations: RCT, randomized controlled trial; Mand, mandibular third molar surgery; OAA/S, observer assessment of alertness/sedation; BIS, bispectral index; HR, heart rate; SBP, systolic blood pressure; NR, not reported.